Michelle Gilson
Stock Analyst at Morgan Stanley
(1.08)
# 3,862
Out of 5,122 analysts
31
Total ratings
32.14%
Success rate
-6.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michelle Gilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Upgrades: Overweight | $10 → $20 | $7.68 | +160.42% | 4 | Jan 9, 2025 | |
| CORT Corcept Therapeutics | Initiates: Buy | $30 | $40.70 | -26.29% | 1 | Feb 2, 2022 | |
| RZLT Rezolute | Maintains: Buy | $30 → $17 | $3.15 | +439.68% | 2 | Nov 29, 2021 | |
| ASND Ascendis Pharma | Maintains: Buy | $190 → $196 | $224.75 | -12.79% | 5 | Jun 1, 2021 | |
| TVTX Travere Therapeutics | Maintains: Buy | $48 → $45 | $32.84 | +37.03% | 3 | May 27, 2021 | |
| STOK Stoke Therapeutics | Maintains: Buy | $72 → $76 | $33.79 | +124.92% | 4 | Mar 11, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $95 → $91 | $57.61 | +57.96% | 12 | Mar 1, 2021 |
Vir Biotechnology
Jan 9, 2025
Upgrades: Overweight
Price Target: $10 → $20
Current: $7.68
Upside: +160.42%
Corcept Therapeutics
Feb 2, 2022
Initiates: Buy
Price Target: $30
Current: $40.70
Upside: -26.29%
Rezolute
Nov 29, 2021
Maintains: Buy
Price Target: $30 → $17
Current: $3.15
Upside: +439.68%
Ascendis Pharma
Jun 1, 2021
Maintains: Buy
Price Target: $190 → $196
Current: $224.75
Upside: -12.79%
Travere Therapeutics
May 27, 2021
Maintains: Buy
Price Target: $48 → $45
Current: $32.84
Upside: +37.03%
Stoke Therapeutics
Mar 11, 2021
Maintains: Buy
Price Target: $72 → $76
Current: $33.79
Upside: +124.92%
BioMarin Pharmaceutical
Mar 1, 2021
Maintains: Buy
Price Target: $95 → $91
Current: $57.61
Upside: +57.96%